Root Financial Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Root Financial Partners’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$515	Buy	+44	New	+$719	﹤0.01%	3218

Other funds holding MLTX

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Bulwark Capital Fernandina Beach, Florida $189M AUM 7.81% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Root Financial Partners's MLTX Position: Q3 2026 in Review

Root Financial Partners opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 44 shares worth $515. The stake represents ﹤0.01% of the portfolio and ranks #3218 among its holdings.

12 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

Root Financial Partners held 44 shares of MoonLake Immunotherapeutics worth $515 as of Q3 2026.
MoonLake Immunotherapeutics was a new Root Financial Partners position in Q3 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3218 holding.
12 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.